Monograph Details
|
|
Cardiovascular System
> Hypertension
|
|
ATACAND HCT 32-12.5 |
| Manufacturer |
|
AstraZeneca Pharmaceuticals |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Angiotensin II receptor blocker + diuretic. |
| Generic Name |
|
Candesartan cilexetil 32mg, hydrochlorothiazide 12.5mg; tabs. |
| Also |
|
• ATACAND HCT 16-12.5
|
| Indications |
|
Hypertension. |
| Children |
|
Not recommended. |
| Adults |
|
Not for initial therapy. May be substituted for titrated components. BP not controlled on HCTZ 25mg once daily, or controlled but serum potassium decreased: one Atacand HCT 16–12.5 tab once daily. BP not controlled on candesartan 32mg per day: initially one Atacand HCT 32–12.5 tab once daily; may increase to 32–25 once daily. CrCl ≤30mL/min: not recommended. |
| Contraindications |
|
Anuria. Sulfonamide allergy. Pregnancy (Cat.D in 2nd and 3rd trimesters). |
| Precautions |
|
Correct hypovolemia before starting, or monitor closely. Renal or hepatic dysfunction. Renal artery stenosis. Asthma. Diabetes. Postsympathectomy. SLE. Gout. Monitor electrolytes. Elderly. Pregnancy (Cat.C in 1st trimester). Nursing mothers: not recommended. |
| Interactions |
|
Digitalis, lithium toxicity (monitor). Adjust antidiabetic, antigout medications. Hyperkalemia with K+ supplements, K+ sparing diuretics, K+ containing salt substitutes. Hypokalemia with corticosteroids, ACTH. Orthostatic hypotension potentiated by alcohol, CNS depressants. Antagonized by NSAIDs. Potentiates other antihypertensives. May potentiate nondepolarizing muscle relaxants. May interfere with parathyroid tests. May antagonize pressor amines. |
| Adverse Reactions |
|
Back pain, dizziness, orthostatic hypotension, electrolyte disturbances, hyperglycemia, hyperuricemia, adverse lipid values, rhabdomyolysis (rare). |
| How Supplied |
|
Tabs—90 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
